<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555305</url>
  </required_header>
  <id_info>
    <org_study_id>13877</org_study_id>
    <secondary_id>I4L-MC-ABEF</secondary_id>
    <nct_id>NCT03555305</nct_id>
  </id_info>
  <brief_title>A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants</brief_title>
  <official_title>Relative Bioavailability of LY2963016 to LANTUS® After Single-Dose Subcutaneous Administration in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in&#xD;
      healthy Chinese participants. Blood samples will be taken to compare how the body handles the&#xD;
      drugs and how they affect blood sugar levels. Side effects and tolerability will be&#xD;
      documented. The study will last at least 18 days, not including screening. Screening is&#xD;
      required within 4 weeks prior to the start of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus</measure>
    <time_frame>-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose</time_frame>
    <description>Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin glargine and Lantus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus</measure>
    <time_frame>-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose</time_frame>
    <description>PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin glargine and Lantus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>30 minutes predose through 24 hours postdose</time_frame>
    <description>Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Maximum Glucose Infusion Rate (Rmax)</measure>
    <time_frame>30 minutes predose through 24 hours postdose</time_frame>
    <description>Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 0.5 U/Kg of Lantus subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <other_name>LY2963016</other_name>
    <other_name>Basaglar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Lantus</arm_group_label>
    <other_name>Insulin Glargine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are native Chinese men or women. Native Chinese is defined as a participant who has&#xD;
             both parents and all 4 grandparents of Chinese origin.&#xD;
&#xD;
          -  For females of childbearing potential (defined as not surgically sterilised and&#xD;
             between menarche and 1-year postmenopause) only:&#xD;
&#xD;
               -  Negative serum pregnancy test at the time of screening.&#xD;
&#xD;
               -  Are not lactating.&#xD;
&#xD;
               -  Intend not to become pregnant during the study.&#xD;
&#xD;
               -  Are sexually inactive or have practiced a reliable method of birth control for at&#xD;
                  least 6 weeks prior to screening.&#xD;
&#xD;
               -  Agree to continue to use a reliable method of birth control (as determined by the&#xD;
                  investigator) during the study.&#xD;
&#xD;
          -  For females not of childbearing potential, must be:&#xD;
&#xD;
               -  Surgically sterile, defined as having had a hysterectomy or bilateral&#xD;
                  oophorectomy or tubal ligation, and/or&#xD;
&#xD;
               -  Menopausal, defined as having had no menses for at least 1 year, or a plasma&#xD;
                  follicular stimulating hormone value of &gt;40 milli-international units per&#xD;
                  milliliter (mIU/mL) and no menses for at least 6 months, unless the participant&#xD;
                  is taking hormone-replacement therapy.&#xD;
&#xD;
          -  Having fasting plasma glucose &lt;110 milligrams per deciliter (mg/dL) (&lt;6.1 millimoles&#xD;
             per liter [mmol/L]) and 2-hour glucose level &lt;140 mg/dL (&lt;7.8 mmol/L) on the 75 grams&#xD;
             (g) oral glucose tolerance test.&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18 and 28 kilograms per meter squared (kg/m²),&#xD;
             inclusive, at screening.&#xD;
&#xD;
          -  Are nonsmokers, have not smoked for at least 6 months prior to entering the study, and&#xD;
             agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Have normal blood pressure and pulse rate at screening, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Have an electrocardiogram (ECG), at screening, considered as within normal limits by&#xD;
             the investigator.&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range for the population&#xD;
             or investigator site, or results with acceptable deviations that are judged to be not&#xD;
             clinically significant by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of first-degree relatives known to have diabetes mellitus.&#xD;
&#xD;
          -  Have known allergies to insulin glargine or its excipients, or related drugs, or&#xD;
             heparin, or have a history of relevant allergic reactions of any origin.&#xD;
&#xD;
          -  Have a significant history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, haematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs; of&#xD;
             constituting a risk when taking the study medication; or of interfering with the&#xD;
             interpretation of data.&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus infection (HIV) and/or positive human&#xD;
             HIV antibodies.&#xD;
&#xD;
          -  Have positive hepatitis B surface antigen.&#xD;
&#xD;
          -  Have donated &gt;400 mL of blood in the last 6 months or donated &gt;100 mL within the last&#xD;
             30 days.&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14&#xD;
             units per week (females), or are unwilling to stop alcohol consumption while resident&#xD;
             in the clinical research unit (CRU) (1 unit = 12 ounces or 360 mL of beer; 5 ounces or&#xD;
             150 mL of wine; 1.5 ounces or 45 mL of distilled spirits).&#xD;
&#xD;
          -  Intend to use: prescription medication or over-the-counter medication or Chinese&#xD;
             traditional medicine within 14 days before dosing (apart from vitamin/mineral&#xD;
             supplements, occasional paracetamol, thyroid replacement, or birth control methods).&#xD;
             If this situation arises, an otherwise suitable participant may be included at the&#xD;
             discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 15, 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <results_first_submitted>October 30, 2020</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 24, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03555305/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03555305/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two period crossover study, with a minimum of 7 days washout period between each period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Period 1: Participants received 0.5 units per kilogram (U/kg) of Insulin glargine subcutaneously.&#xD;
Period 2: Participants received 0.5 U/Kg of Lantus subcutaneously.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Period 1: Participants received 0.5 U/Kg of Lantus subcutaneously. Period 2: Participants received 0.5 U/Kg of Insulin glargine subcutaneously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Participants received 0.5 U/Kg of Insulin glargine and Lantus subcutaneously as per dosing schedule.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus</title>
        <description>Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin glargine and Lantus.</description>
        <time_frame>-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 U/kg Insulin Glargine</title>
            <description>Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>0.5 U/kg Lantus</title>
            <description>Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus</title>
          <description>Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin glargine and Lantus.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>picomole per liter (pmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="31"/>
                    <measurement group_id="O2" value="129" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis was performed using linear mixed effects model and participant as a random effect, with period, sequence, and treatment as fixed effects. The estimate of the ratio of means of each PK/PD parameters between the 2 treatments and the corresponding 90% confidence interval were calculated. A typical bio-equivalence limit (0.8 to 1.25) was used as equivalence margin.</non_inferiority_desc>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>0.961</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.886</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus</title>
        <description>PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin glargine and Lantus.</description>
        <time_frame>-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 U/kg Insulin Glargine</title>
            <description>Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>0.5 U/kg Lantus</title>
            <description>Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus</title>
          <description>PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin glargine and Lantus.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>picomole*hour per liter (pmol*hr/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2170" spread="28"/>
                    <measurement group_id="O2" value="2310" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis was performed using linear mixed effects model and participant as a random effect, with period, sequence, and treatment as fixed effects. The estimate of the ratio of means of each PK/PD parameters between the 2 treatments and the corresponding 90% confidence interval were calculated. A typical bio-equivalence limit (0.8 to 1.25) was used as equivalence margin.</non_inferiority_desc>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>0.943</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.874</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)</title>
        <description>Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.</description>
        <time_frame>30 minutes predose through 24 hours postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable Gtot data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 U/kg Insulin Glargine</title>
            <description>Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>0.5 U/kg Lantus</title>
            <description>Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)</title>
          <description>Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable Gtot data.</population>
          <units>milligrams/kilogram (mg/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2390" spread="43"/>
                    <measurement group_id="O2" value="2680" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Maximum Glucose Infusion Rate (Rmax)</title>
        <description>Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.</description>
        <time_frame>30 minutes predose through 24 hours postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable Rmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 U/kg Insulin Glargine</title>
            <description>Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>0.5 U/kg Lantus</title>
            <description>Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Maximum Glucose Infusion Rate (Rmax)</title>
          <description>Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable Rmax data.</population>
          <units>milligrams/kilograms/minute (mg/kg/min)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="37"/>
                    <measurement group_id="O2" value="2.99" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 Days</time_frame>
      <desc>All randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.5 U/kg Insulin Glargine</title>
          <description>Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.</description>
        </group>
        <group group_id="E2">
          <title>0.5 U/kg Lantus</title>
          <description>Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

